226 The Role of CCL21 in the Formation of Lymphoid-Like Stroma in Chronic Graft Dysfunction after Lung Transplantation

2011 ◽  
Vol 30 (4) ◽  
pp. S81-S82
Author(s):  
Y. Matsuda ◽  
M. Sato ◽  
S. Hirayama ◽  
G. Zehong ◽  
J. Yeung ◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Graft Dysfunction ◽  
Chronic Graft Dysfunction

scholarly journals Role of Donor Microbiota in the Development of Primary Graft Dysfunction Following Human Lung Transplantation

2016 ◽  
Vol 35 (4) ◽  
pp. S87-S88
Author(s):  
Z. Xu ◽  
R. Schuessler ◽  
D. Nayak ◽  
W. Yang ◽  
E. Trulock ◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Human Lung ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction

Primary Graft Dysfunction in Lung Transplantation: The Role of CD26/Dipeptidylpeptidase IV and Vasoactive Intestinal Peptide

2009 ◽  
Vol 87 (8) ◽  
pp. 1140-1146 ◽  
Author(s):  
Wei Zhai ◽  
Wolfgang Jungraithmayr ◽  
Ingrid De Meester ◽  
Ilhan Inci ◽  
Koen Augustyns ◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Vasoactive Intestinal Peptide ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Dipeptidylpeptidase Iv

Navigating the Road to Transplant in Pulmonary Arterial Hypertension: A Road Less Taken

2016 ◽  
Vol 15 (1) ◽  
pp. 12-13
Author(s):  
Adaani E. Frost ◽  
Harrison W. Farber
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Lung Transplantation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Donor Organ ◽  
The Road ◽  
Lung Allocation Score ◽  
Pulmonary Arterial

Dramatic advances in therapy for pulmonary arterial hypertension (PAH) in the last 20 years have improved survival from a median of 2.5 years in the pretreatment era to 7.5 years currently. However, impressive as that may seem, it is important to note that a median survival of 7.5 years is equivalent to that of surgically resected non-small cell lung cancer, thus underscoring the importance of lung transplantation as a treatment option in patients with PAH. In this edition of Advances, Edelman has reviewed the pathway to transplantation for patients with PAH, detailing the recommendations for timing of referral, listing for lung transplantation, the role of the lung allocation score in allocating a donor organ, and the outcome of lung transplantation.

scholarly journals Recent advances in lung transplantation

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1684 ◽  
Author(s):  
Keith C Meyer
Keyword(s):  
Lung Transplantation ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Donor Pool ◽  
Post Transplant ◽  
Antibody Mediated Rejection ◽  
The Past ◽  
End Stage ◽  
Transplant Complications

Lung transplantation can improve quality of life and prolong survival for individuals with end-stage lung disease, and many advances in the realms of both basic science and clinical research aspects of lung transplantation have emerged over the past few decades. However, many challenges must yet be overcome to increase post-transplant survival. These include successfully bridging patients to transplant, expanding the lung donor pool, inducing tolerance, and preventing a myriad of post-transplant complications that include primary graft dysfunction, forms of cellular and antibody-mediated rejection, chronic lung allograft dysfunction, and infections. The goal of this manuscript is to review salient recent and evolving advances in the field of lung transplantation.

Sign in / Sign up

Export Citation Format

Share Document